Novel series of nitric oxide-releasing thiazolidine-2,4-diones (
NO-TZD-3a-d,5,6
) and 3,4,5-trimethoxychalcone-based multifunctional 1,4-dihydropyrimidines (
CDHPM-10a-g
) have been designed and synthesised as potent broad-spectrum anticancer agents with potential VEGFR-2 inhibition. The designed analogs were evaluated for their anticancer activities towards a full panel of NCI-60 tumour cell lines and
CDHPM-10a-g
emerged mean %inhibitions ranging from 76.40 to 147.69%. Among them,
CDHPM-10e
and
CDHPM-10f
demonstrated the highest MGI% of 147.69 and 140.24%, respectively. Compounds
CDHPM-10a,b,d-f
showed higher mean %inhibitory activity than the reference drug sorafenib (MGI% = 105.46%). Superiorly, the hybrid
CDHPM-10e
displayed the highest potencies towards all the herein tested subpanels of nine types of cancer with MGI
50
of 1.83 µM. Also, it revealed potent cytostatic single-digit micromolar activity towards the herein examined cancer cell lines. The designed compounds
CDHPM-10a-g
were exposed as potent non-selective broad-spectrum anticancer agents over all NCI subpanels with an SI range of 0.66–1.97. In addition, the target analog
CDHPM-10e
revealed potency towards VEGFR-2 kinase comparable to that of sorafenib with a sub-micromolar IC
50
value of 0.11 µM. Also,
CDHPM-10e
could effectively induce Sub-G1-phase arrest and prompt apoptosis
via
caspase and p53-dependent mechanisms. Furthermore,
CDHPM-10e
revealed significant anti-metastatic activity as detected by wound healing assay. The modelling study implies that
CDHPM-10e
overlaid well with sorafenib and formed a strong H-bond in the DFG binding domain. The ADMET studies hinted out that
CDHPM-10e
met Pfizer’s drug-likeness criteria. The presented novel potent anticancer agent merits further devotion as a new lead product in developing more chalcone-based VEGFR-2 inhibitors.